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ABSTRACT 
 
 
THE STEROID SULFATASE INHIBITOR (p-O-SULFAMOYL) –  
TETRADECANOYL TYRAMINE (DU-14) ENHANCES MEMORY RETENTION IN 
PASSIVE AVOIDANCE IN RATS WITH HIPPOCAMPAL CHOLINERGIC DEFICIT  
 
 
By 
 
Phebian Arinola Abitoye 
 
May 2008 
 
 
 
Thesis Supervised by David A. Johnson, PhD. 
 
Neurosteroids, such as dehydroepiandrosterone sulfate, (DHEAS) are steroidal 
compounds synthesized within the central nervous system that modulate its function.  
Among the effects associated with sulfated neurosteroids is the enhancement of memory. 
Previous studies have demonstrated that altering the metabolism of neurosteroids via 
inhibition of the enzyme steroid sulfatase could reverse scopolamine-induced amnesia.  
p-O-(Sulfamoyl) - tetradecanoyl tyramine (DU-14) is a steroid sulfatase inhibitor (SSI) 
that prevents the conversion of DHEAS to DHEA thereby increasing the concentration of 
sulfated neurosteroids to potentiate the effect of endogenous DHEAS.  To determine 
whether DU-14 could enhance memory retention for footshock in rats with hippocampal 
cholinergic hypofunction, male Sprague-Dawley rats were infused with the immunotoxin 
192 IgG-saporin (SAP) into the medial septum, and tested using a step-through passive 
avoidance paradigm.  There was a greater than 80% decrease in ChAT activity in the 
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hippocampi of animals treated with SAP (p<0.0001).  There was also a 24.1% decrease in 
ChAT activity of in the frontal cortex of SAP animals administered DU-14.  However, 
this small but significant decrease did not affect locomotor behavior in rats.  
Administration of DU-14 enhanced memory retention for 1.0 mA and not 1.25 mA 
footshock in animals with SAP lesion compared to vehicle treated SAP animals (p< 
0.05).  The effect of DU-14 on locomotor activity was also investigated.  DU-14 did not 
affect locomotor activity during acclimation or retention. These results suggest that DU-
14 may enhance memory retention in rats with hippocampal cholinergic lesion.   
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I. INTRODUCTION 
 
A. Statement of Problem 
Alzheimer’s disease, the most common form of senile dementia, is a progressive 
neurodegenerative disorder characterized by memory loss and behavioral changes.  It is a 
major killer diseases ranking fourth or fifth in the United States.  Alzheimer’s disease 
affects memory functions predominantly related to the hippocampus and the cerebral 
cortex and is associated with a significant loss of cholinergic neurons.  This disease is 
projected to increase in prevalence during the coming decades, as the life span of United 
States population gets longer. With more drugs becoming available, it may become 
possible to delay disease progression for many years [1].  A few partially successful 
therapies for the treatment and /or prevention of the disorder include augmentation of 
brain cholinergic function by inhibitors of acetylcholinesterase (AChE), e.g., 
physostigimine, tacrine and donepezil. An alternative strategy is the use of NMDA 
glutamate receptor antagonist memantine [2].  Another approach currently being 
investigated is the modulation of the major inhibitory GABA neurons.  Neurosteroids 
have been implicated in memory enhancement over the past decade [3, 4] and further 
research has shown that preventing the conversion of these steroids, especially DHEAS, 
to the unsulfated form can enhance memory function [5].  The goal of this project is to 
determine whether chronic administration of a steroid sulfatase inhibitor, DU-14, can 
enhance memory retention in rats with a saporin induced selective cholinergic deficit. 
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B. Literature Review 
1. Learning and Memory 
Learning is the acquisition and retention of memories and behaviors including 
skills, knowledge, understanding, values and wisdom.  It is the goal of education and the 
product of experience.  It can also be said to be a relatively permanent process that is 
inferred from performance changes due to practice. Thus skills in reading, which 
obviously result from practice, are instances of learning. Similarly, improvement in 
athletic skills such as golf or tennis are instances of learning because they involve 
changes which can be attributed to a practice condition [6].  The current understanding of 
neurons and central nervous system (CNS) function implies that the process of learning 
corresponds to changes in the relationship between certain neurons in the brain. 
Generally however, it is recognized that the retention of memories comes easier when 
parts of the brain that control multiple functions such as hearing, seeing, smelling, motor 
skills, touch sense, the application of informal names and reason are stimulated.  
Memory on the other hand can be defined as a behavioral change caused by a 
previous experience [7].  Memory is a fundamental process, and without memory, there is 
a capability of nothing but simple reflexes and stereotyped behaviors.  Thus, learning and 
memory are one of the most intensively studied subjects in the field of neuroscience [7].  
Learning and memory are two distinct, yet intimately associated, processes.  Quite 
simply, without memory, there is no learning [8].  In psychology, memory is an 
organism’s ability to store, retain, and subsequently recall information. Traditional 
studies of memory began in the realm of philosophy, including techniques of artificially 
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enhancing the memory. The late nineteenth and early twentieth century put memory 
within the realm of cognitive psychology.  
 
Memory classification 
There are several ways to classify memories, based on duration, nature, and 
retrieval of information.  
 
Classification based on processing 
From an information processing perspective, there are three main stages in the 
formation and retrieval of memory: 
• Encoding or registration (processing and combining of received information) 
• Storage (creation of a record of the encoded information) 
• Retrieval or recall (calling back the stored information in response to some cue      
for use in a process or activity) 
 
Classification based on duration 
A basic and generally accepted classification of memory is based on the duration 
of memory retention. In this classification system there are four distinct types of memory: 
sensory memory, short-term memory, intermediate memory and long-term memory. 
 
Sensory memory 
 This can also be referred to as immediate memory [9]. Sensory memory 
corresponds approximately to the initial 200-500ms after an item is perceived.  The 
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ability to look at an item, and remember what it looked like with just a second of 
observation is an example of sensory memory.  With very short presentations, 
participants often report that they seem to “see” more than they can actually report.  This 
type of memory cannot be prolonged via rehearsal. 
 
Short-term Memory 
 Some of the information in sensory memory is then transferred to short-term 
memory.  Short-term memory allows one to retain something from several seconds to as 
long as a minute without rehearsal.  Its capacity is also very limited.  A conventional way 
of testing the integrity of short-term memory is to present a string of randomly ordered 
digits, which the individual is then asked to repeat [9]. A special sort of short-term 
memory is called working memory.  This refers to the ability to hold information in mind 
long enough to carry out sequential actions [10].  An example is searching for a lost 
object; working memory allows the hunt to proceed efficiently, avoiding places already 
inspected. A particular advantage to this type of memory is that it can be readily 
examined in experimental animals [9]. 
 
 
Figure  1: The major temporal categories of human memory [9] 
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Intermediate memory 
This type of memory occurs once short-term memory has been processed.  It lasts 
from minutes to hours.  It is the part of memory which holds and mixes information from 
the different parts of memory.  
 
Long-term memory 
The storage in sensory, short-term and intermediate memories generally has a 
strictly limited capacity and duration, meaning that information is available over a certain 
period of time, but is not retained indefinitely.  By contrast, long-term memory can store 
much larger quantities of information for potentially unlimited duration (sometimes a 
whole life span).  Short-term memory is supported by transient patterns of neuronal 
communication, dependent on regions of the frontal lobe (especially dorsolateral 
prefrontal cortex) and parietal lobe.  Long-term memories, on the other hand, are 
maintained by more stable and permanent changes in neural connections widely spread 
through the brain.  
 
The most popular candidate site for memory storage is the synapse or set of 
synapses, where nerve cells (neurons) communicate.  A change in transmission efficacy 
at the synapse has been considered to be the mechanism of memory [7].  It is widely 
accepted that protein synthesis, including local synthesis at synapses, enables the control 
of synaptic strength independent of cell body via rapid protein production from pre-
existing mRNA, and this is required for several forms of synaptic plasticity [11-13].  This 
is rooted in the fact that synaptic plasticity is a physiological phenomenon whereby 
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specific patterns of neural activity give rise to changes in synaptic efficacy and neural 
excitability that long outlast the event that trigger them [14].  Memory entails a number 
of biological strategies and anatomical substrates that are unlikely to be explained in 
terms of any particular cellular or molecular mechanism.  Various neurotransmitters in 
the brain, including cholinergic, γ- aminobutyric acid, adrenergic and glutamertergic 
systems have been shown to play a significant role in memory function  [15-17]. 
 
2. The Cholinergic System  
The cholinergic system is one of the most important modulatory neurotransmitter 
systems in the brain [2, 18], and has long been recognized as playing a key role in the 
regulation of cognitive functions [2, 17, 19, 20]. Briefly, the cholinergic system is 
distributed in a variety of different nuclei of which two groups (basal forebrain and 
pedunculopontine) have extensive projections to the cortex and thalamus. 
Pedunculopontine cholinergic neurons are considered to control rapid eye movement 
sleep or dreaming while basal forebrain cholinergic pathways appear to generate and 
integrate consciousness and awareness [18].  The cholinergic system is involved in higher 
brain functions,
 
including learning and memory.  The hippocampal region of the brain is 
extensively innervated by
 
cholinergic fibers originating mainly from the septal nucleus, 
and the vertical limb of the diagonal band of Broca [21, 22]. 
The role of acetylcholine in memory has been well established. The 
neurophysiological activity of ACh has been known since the turn of the century and its 
neurotransmitter role since the mid-1920s [23].  Acetylcholine is synthesized in a 
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reaction catalyzed by choline acetyltransferase (ChAT) and broken down by another 
enzyme called acetylcholinesterase (AChE). 
 
Acetyl CoA + Choline  ACh + CoA 
 
The acetyl CoA for ACh synthesis arises from glucose through glycolysis and the 
pyruvate dehydrogenase system [23, 24].  Choline on the other hand can be obtained 
either from the hydrolysis of acetylcholine or breakdown of phosphatidylcholine, a 
membrane phospholipid. 
 
Cholinergic pathways in the central nervous system (CNS) 
The identification of cholinergic synapses in the peripheral nervous system was 
relatively easy, and it has been known that acetylcholine is the transmitter at autonomic 
ganglia, at the parasympathetic postganglionic synapses and the neuromuscular junction  
[2, 23].  In the CNS, cholinergic neurons exhibit two basic organization schemata: local 
circuit cells and projection neurons.  Local circuit cells (i.e. those that are 
morphologically arrayed wholly within the neural structure in which they are found) are 
exemplified by the interneurons of the caudate-putamen nucleus, nucleus accumbens, 
olfactory tubercle and Islands of Calleja complex.  Projection neurons connect two or 
more different regions.  Of the cholinergic projection neurons that interconnect central 
structures, two major subconstellations have been identified.  The first is the basal 
forebrain cholinergic complex composed of ChAT-positive neurons in the medial septal 
nucleus, diagonal band nuclei, substantial innominata, magnocellular preoptic field, and 
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nucleus basalis, all of which project to the entire nonstriatal telenecephalon. The second 
is the pontomesencephalotegmental cholinergic complex composed of ChAT-
immunoreactive cells in the pendunculopontine and laterodorsal tegmental nuclei, which 
projects ascendingly to the thalamus and other diencephalic loci and descendingly to the 
pontine and medullary reticular formations, deep cerebellar and vestibular nuclei, and 
cranial nerve nuclei [23]. 
 
Cholinergic receptors 
Cholinergic receptors fall into two classes, muscarinic and nicotinic.  In 
mammals, five distinct subtypes of muscarinic ACh receptors (mAChRs) have been 
identified, each produced by a different gene.  These variants have distinct anatomical 
locations in the periphery and CNS and differing chemical specificities.   They are G 
protein-coupled receptors (GPCRs) linked to a variety of second messenger systems.  
When activated, they act either directly on ion channels or are linked to a variety of 
second messenger system.  The final effect can be to open or close potassium, calcium or 
chloride channels leading to either a depolarization or a hyperpolarization of neurons.  
M1, M3, and M5 are coupled to phosphatidyl inostol hydrolysis while M2 and M4 are 
coupled to cAMP.  The nicotinic ACh receptors (nAChRs) are members of a superfamily 
of ligand gated ion channels.  Each receptor is made up of five receptor subunits arranged 
symmetrically around a central pore structure whose activation always causes a rapid 
increase in cellular permeability to sodium and calcium, depolarization and excitation. 
The receptors exist at the skeletal neuromuscular junction, autonomic ganglia, adrenal 
medulla and in the CNS  [2, 23].   
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The cholinergic system and memory 
Both muscarinic and nicotinic cholinergic receptors have been shown to be 
involved in cognitive function [25].  However, the action of ACh on learning
 
and 
memory is mostly mediated by mAChRs [22].  Cholinergic transmission at the mAChRs 
has been implicated in learning and memory in humans
 
and other mammals and also 
shown to be important in the active maintenance of short-term memories and 
hippocampal plasticity [10, 25, 26].   
The role of muscarinic receptors in memory function is evident in studies of M2 
muscarinic acetylcholine receptor knock out mice that show deficits in behavioral 
flexibility, working memory and hippocampal plasticity [26].  The experiments included 
two different hippocampus–dependent spatial learning and memory tasks; the Barnes 
circular maze test and the T-maze delayed alternation task. Significant deficits in 
behavioral flexibility and working memory were demonstrated to be associated with 
pronounced impairments in neuronal plasticity at the Schaffer collateral-CA1 synapse in 
M2-/- mice.  In summary, the study found that M2 receptors are involved in processes that 
facilitate working memory.  
Drugs that elevate, mimic, or inhibit the breakdown of ACh improve learning and 
memory performance [25]. Cholinergic innervations
 
of the cerebral cortex and the 
hippocampus originate primarily
 
from the cholinergic basal nuclear complex.  Lesions
 
of 
these basal forebrain cholinergic neurons have been reported to result
 
in impairment in 
memory, learning, and attention, whereas cholinergic
 
agonists facilitate learning and 
memory [27].  Conversely, drugs that deplete ACh or compete for its receptor sites 
reduce performance of memory tasks.  
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Dementia of the Alzheimer's type involves loss of ACh activity, and cellular 
degeneration in the nucleus basalis of Meynert (nbM) and the cortex. Nicotinic 
cholinergic neurons are especially depleted [25].  The degeneration of forebrain 
cholinergic projections is one of the most salient neurochemical features of Alzheimer’s 
disease AD, although other transmitter systems are also altered in some, but not all, 
patients.  
Cholinergic based therapies of AD have generally failed thus far, or resulted in 
limited clinical improvements [28].  To date, attempts to treat progressive dementia with 
cholinergic replacement have been generally disappointing.  The hope was that 
facilitation of ACh function might be therapeutic in a fashion analogous to levodopa 
treatment in Parkinson's disease, but most studies have reported only modest reduction of 
dementia following ACh therapy.  More recently, drugs such as the AChE inhibitor 
donepezil (a cerebroselective and reversible anti-AChE) have targeted the cholinergic 
system for treatment of the memory loss associated with Alzheimer's disease [25, 28, 29].  
Another approach is based on the use of precursors of acetylcholine (e.g. lecithin or 
Choline).   Functional data from various laboratories now suggest that the drugs used in 
clinical trials may not have been ideal, since they can result in the activation of 
presynaptically located negative M2-muscarinic autoreceptors either by increasing the 
half-life of ACh or by direct stimulation by agonists that would inhibit the subsequent 
release of ACh from remaining functional synapses.  Moreover, it has recently been 
demonstrated that the normal processing of the ß-amyloid precursor is influenced by 
cholinergic activity [28].  Hence, altered cholinergic innervation could lead to an aberrant 
processing of ß-amyloid and possible formation of neurotoxic fragments leading 
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ultimately to neuritic plaque formation. In addition, in the advanced stage of this 
progressive form of dementia, extensive loss of cholinergic neurons could prevent 
individuals from being responsive to therapeutic agents that would target those sites. 
Whereas
 
most published research has focused on the importance of 
septohippocampal
 
cholinergic mechanisms in learning and memory and in
 
generation of 
the theta rhythm (a wave pattern electroencephalogram in the frequency band of 4-7Hz) 
[30], the role of septohippocampal GABAergic
 
neurons is increasingly recognized, 
especially with regard
 
to production of theta activity.  Wu et al. [21] suggested that 
activation of septohippocampal GABA neurons, and not septohippocampal cholinergic 
neurons,
 
may underlie the behavioral and electrophysiological effects observed
 
after 
intraseptal infusions of muscarinic agonists in rats.  
 
3. The GABAergic system and memory 
The amino acid γ-aminobutyric acid (GABA) is the major inhibitory 
neurotransmitter in the mammalian CNS [2].  GABA was first identified as a unique 
chemical constituent of the brain in 1950, but its potency as a CNS depressant was not 
immediately recognized.  GABA was initially identified as the only inhibitory amino acid 
found exclusively in nerves that inhibit the crustacean stretch receptor; moreover, the 
GABA content accounted for the inhibitory potency of extracts from these nerves.  
Finally, GABA release correlated with the frequency of nerve stimulation, and identical 
increases in muscle chloride conductance accompanied GABA application and 
stimulation of the inhibitory nerve. These same physiological and pharmacological 
properties helped to establish a role for GABA in the mammalian CNS [31, 32].  There is 
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substantial data to support the idea that GABA is found primarily in inhibitory 
interneurons impinging on and modulating activity in the vertebrate brain and plays an 
important role in information processing.  GABA is thought to regulate the balance of 
excitatory and inhibitory states in the cortex and hippocampus and GABA receptor 
agonists and antagonists have been variously demonstrated to enhance or inhibit memory 
processing [31].   
GABA receptors have been divided into three main types: A, B and C.  The most 
prominent GABAA-receptor subtype is a ligand-gated chloride ion channel, an ionotropic 
receptor that is opened after release of GABA from presynaptic neurons.  The GABAB 
receptor is a G protein-coupled receptor (GPCR), while the GABAC receptor is a 
transmitter-gated chloride channel [2].   
GABAA receptors are the major inhibitory neurotransmitter receptors in the brain 
and the site of action of many clinically important drugs [32].  Synaptically-released 
GABA acts at the GABAA ligand-gated ion channel present on the postsynaptic 
membrane to produce membrane hyperpolarization through an increase in chloride 
conductance that comprises fast inhibitory post synaptic potentials, IPSPs [31].  This 
decreases the depolarizing effect of an excitatory input, thus depressing excitability [32]. 
GABAA channels typically consist of two α, two β and one γ subunit.  GABAA is present 
throughout the mammalian CNS and is the primary effector of GABA-mediated IPSPs.  
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Figure 2: Schematic illustration of GABAA receptors containing two α and ß subunits and 
a single γ subunit. 
GABA is an agonist to the GABA channel receptor but not the only molecule that can modify this channel 
receptor’s opening. Other molecules can also affect it, such as the benzodiazepines, barbiturates, picrotoxin 
and steroids. By binding to this receptor at different sites from GABA, these molecules modulate the 
receptor by causing either an opening (e.g. benzodiazepines) or closing (e.g. steroid) of the chloride ion 
channel  [32]. 
 
Neuroactive steroids such as estradiol, progesterone, and progesterone's 
metabolite- allopregnanolone (ALLO) modulate the function of neurotransmitters 
implicated in regulation, cognition, and behavior.  Estradiol enhances neuronal 
excitability in structures such as the hippocampus via modulation of glutamatergic 
NMDA receptors.  It also has antagonist activity at the GABAA receptor by reducing the 
GABA-mediated inhibition.  In contrast, the progesterone metabolite ALLO is a potent 
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GABAA receptor agonist with anticonvulsant, hypnotic, and anxiolytic effects.  As the 
primary inhibitory neurotransmitter, GABA is released by neurons throughout the brain 
and has numerous interactions with other neurotransmitter systems. Thus, substances 
which modulate GABA neurotransmission will not only alter the balance in neuronal 
excitation and inhibition but are likely to alter the activity of neurons from multiple 
systems [33].  That the GABAA receptor, is sensitive to physiologic changes in estradiol 
and ALLO levels suggests that this area would be fertile ground for research in memory 
function.  
 
4. Neurosteroids  
The term “neurosteroid” (NS), defined as steroids produced within the nervous 
system, was first introduced by Baulieu in 1981 [30]. The neurosteroid 
dehydroepiandrosterone sulfate (DHEAS) was found at high levels in the brain long after 
gonadectomy and adrenalectomy, and was later shown to be synthesized by the brain 
[34].  Later, androstenedione, pregnenolone, their sulfates and lipid derivatives, as well as 
tetrahydrometabolites of progesterone (P) and deoxycorticosterone (DOC) were 
identified as neurosteroids.            
There are differences in synthesis pathways for steroids originating in the brain 
and in the adrenals [34].  In the adrenals, the enzymes responsible for synthesis are never 
expressed in the same cell [34, 35].  In the brain, the enzymes are co-expressed not only 
in the same region, but even within the same cell.  Contrary to neurosteroids, neuroactive 
steroids (NAS) refer to steroids that, independent of their origin, are capable of 
modifying neural activities.  NAS bind and modulate different types of membrane 
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receptors.  Neuroactive steroids play a key role in both normal physiology and in the 
pathogenesis of brain diseases [36].  In spite of poor permeability through the blood–
brain barrier for sulfated steroids, high concentrations of DHEA and also its sulfate have 
been found in brain tissues [36].  Physiological concentrations of dehydroepiandrosterone 
(DHEA) and dehydroepiandrosterone sulfate (DHEAS) are maintained by two enzymes 
present in the blood and other peripheral tissues, as well as in the brain, steroid sulfatase 
and neurosteroid sulfuryl transferase. Neurosteroids possess both rapid, non-genomic 
effects, as well slow genomic effects. In contrast to steroids synthesized in classic 
steroidogenic tissues that activate cytoplasmic receptors, neurosteroids predominantly use 
signaling pathways common for neuromodulators.  It is well known that unconjugated 
forms of neurosteroids, such as saturated progesterone metabolites 5α-pregnan-3α-ol-20-
one (allopregnanolone), its 21-hydroxylated metabolite, and also androsterone and 
DHEA act on GABAA receptors as positive modulators that along with other events 
increase the permeability of chloride ion channels.  Sulfated forms of neurosteroids act in 
the opposite way, as negative GABAAR modulators.  Some neurosteroids conjugated 
with sulfuric acid, including DHEAS and pregnenolone sulfate (PregS), are also potent 
positive noncompetitive modulators of NMDA receptors.  ∆
5
-Ene-3-hydroxy steroids 
accumulate in the brain in the form of conjugates, namely, fatty acids esters or sulfates, 
and their formation has been found to be independent of neurosteroid biosynthesis in the 
peripheral endocrine tissues [36].  The typical route of biosynthesis in situ is the 
esterification of a free steroid molecule by neurosteroid sulfuryl transferase (NSST).  
Two enzymes maintain the equilibrium between PregS and Preg or DHEAS and DHEA: 
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steroid sulfatase (EC 3.1.6.2), which catalyzes unconjugated steroid formation and the 
already mentioned NSST, which catalyzes steroid sulfate formation.  
Neurosteroid sulfuryl transferase is a cytosolic enzyme, which catalyzes the 
sulfoconjugation of 3β- or 17β-hydroxysteroids [36].  It utilizes adenosine-3-phosphate-
5-phosphosulfate (PAPS) as a co-substrate, which is formed by a common metabolic 
pathway, regardless of the species or tissue of origin.  The sulfo-conjugation of steroids 
involves the transfer of a sulfonate radical (SO3) from an activated donor molecule 
(PAPS) to a hydroxyl acceptor site.  Steroid sulfatase is bound to the membrane of the 
endoplasmic reticulum, presumably through multiple transmembrane and other 
membrane anchoring segments.  The highest sulfatase activity, therefore, is found mainly 
in the microsomal fraction. Although steroid sulfatases and sulfotransferases from 
various tissues have been well characterized, especially estrone sulfatase in connection 
with breast cancer, there is not enough information about both enzymes in the primate 
brain, despite the fact that they play important roles in brain physiology and 
pathophysiology.  
Quantitatively, the adrenal DHEA and its sulfate ester DHEAS are the most 
abundant C19 steroids circulating in human plasma. Even though the plasma 
concentration of DHEAS decreases with aging, there is still about 1 µM of this 
compound in men and women of advanced age [37].  
Neuroactive steroids bind to and modulate different types of membrane receptors. 
The GABAA and sigma receptor complexes have been the most extensively studied 
although glycine-activated chloride channels, nicotinic acetylcholine receptors 
(constituted in Xenopus laevis oocytes), mouse striatal and thalamic synaptosomes, and 
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voltage-activated calcium channels are also modulated by NAS.  Within the glutamate 
receptor family, NMDA receptors, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic 
acid (AMPA) receptors, and kainate receptors have also been demonstrated to be a target 
for steroid modulation [34].  
Among the effects associated with neurosteroids is the enhancement of memory. 
The mechanism for this enhancement remains unclear; however, DHEAS has been shown 
to reverse scopolamine-induced amnesia [38].  GABAergic agents in the medial septal 
nucleus modulate the activation of the hippocampus and ACh turnover.  In addition, the 
mechanism for reversal of scopolamine-induced amnesia has been associated with 
increased release of ACh [39].  
 
 
 
Figure 3: Neurosteroid biosynthesis and metabolism in the rat brain.  Dotted arrows 
indicate metabolic conversions not yet formally demonstrated [5]. 
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5. Steroid sulfatase enzyme 
Steroid sulfatase (estrone sulfatase, arylsulfatase C, (STS); E.C. 3.1.6.2) is a 
ubiquitous membrane-bound, microsomal enzyme localized mainly in the endoplasmic 
reticulum and the nuclear envelope of cells.  It is an enzyme involved in the local 
production of estrogens and androgens in target organs [40, 41].  It is responsible for the 
hydrolysis of 3β-hydroxy steroid sulfates, such as cholesterol and pregnenolone sulfate, 
and has an important role in regulating the synthesis of estrogenic steroids from estrone 
sulfate and dehydroepiandrosterone sulfate in hormone-dependent tumors [42].  
Preliminary results indicate the importance of estrone sulfate as a potential source of 
estrogen to support the growth of estrogen-dependent breast cancer [43].  In the skin, the 
abundant systemic precursor DHEAS is cleaved by steroid sulfatase to DHEA, which is 
then converted to the bioactive androgens testosterone and dihydrotestosterone. Steroid 
sulfatase inhibition has been proposed as a novel therapeutic concept for the treatment of 
androgen-dependent disorders of the hair follicle, such as androgenic alopecia and 
hirsutism, in addition to acne.   
In the brain, DHEAS is cleaved to DHEA via STS, and inhibition of STS 
enhances learning and spatial memory in rats [44].  Thus, potent inhibitors of estrone 
sulfatase are potential therapeutic agents for treatment of memory loss.  These results 
suggest a possible role for sulfatase enzyme inhibitors in treating Alzheimer’s disease.   
A variety of different reversible and irreversible inhibitors of STS have been 
developed.  The most potent and most commonly used inhibitors are steroidal or 
nonsteroidal O-sulfamates, which irreversibly inactivate the enzyme.  Sulfatase inhibition 
was measured using placental microsomes, lysates of cells transfected with an STS 
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expression vector, or highly purified STS obtained from a cell line stably expressing 
human STS.  Radioactively labeled estrone sulfate or DHEAS and a fluorogenic 
compound, 4-methylumbelliferyl sulfate (4-MUS), are most commonly used as substrates 
for the determination of enzyme activity [40, 41].   
 
6. p-O-Sulfamoyl-N-tetradecanoyl tyramine (DU-14) 
A number of steroid sulfatase inhibitors have been developed including estrone 3-
O-sulfamate (EMATE) (1), estrone 3-O-methylthiophosphonate (2), and estrone 3-
sulfonyl chloride (3). EMATE was the first steroid sulfatase inhibitor exhibiting potent 
active site-directed irreversible inhibition against both E1-STS and DHA-STS, both in 
vitro and in vivo orally or subcutaneously [41].  EMATE was synthesized by treating the 
sodium salt of estrone with sulfamoyl chloride. This compound inhibited not only estrone 
sulfatase but also dehydroepiandrosterone sulfatase activity  in placental microsomes and 
in intact MCF-7 breast cancers [42].  Unexpectedly, however, EMATE was found to be a 
potent estrogen, being five times more active than ethinylestradiol when administered 
orally to rats [41].  The exact reasons why EMATE is such a potent estrogen remain to be 
elucidated.  However, current evidence suggests that it is acting as a prodrug for estrone.  
 
Figure 4: Structures of steroid sulfatase inhibitors (1-3, 5) and estrone oxime (4) 
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Figure 5: Structure of EMATE, (p-O- sulfamoyl)-N –tetradecanoyl tyramine (C2-14) [45]. 
EMATE (1) is one of the most potent steroidal E1-STS inhibitors yet synthesized.  
In vitro, EMATE inhibits E1-STS activity by greater than 99% at 0.1µM in intact MCF-7 
breast cancer cells and in a time- and concentration-dependent manner in a placental 
microsomes preparation, indicating that it acts as an irreversible inhibitor.  Subsequent 
studies have also shown that EMATE inhibits DHA-STS, the enzyme that regulates the 
biosynthesis of the estrogenic steroid androstenediol [41].   
To avoid the problems associated with a potentially active steroid nucleus, a 
series of (p-O-sulfamoyl)-N-alkanoyltyramines as nonsteroidal estrone sulfatase 
inhibitors were synthesized and tested  [46].  The nine compounds differed in the length 
of their alkanoyl chains.  The ability of the (p-O-sulfamoyl)-N-alkanoyl tyramines to 
inhibit: (a) estrone sulfatase activity in intact cultures of human breast cancer cells 
(MDA-MB-231); and (b) the growth of estrogen-dependent human breast cancer cells 
(MCF-7) were tested.  All of the test compounds (1µM) inhibited the estrone sulfatase 
activity of intact MDA-MB-231 cells; however, compounds with a longer alkanoyl chain 
were more effective than those with a shorter chain.  The two most potent compounds 
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were found to be (p-O-sulfamoyl)-N-tridecanoyl tyramine and (p-O-sulfamoyl)-N-
tetradecanoyl tyramine (DU-14).  It was shown that the (p-O-sulfamoyl)-N-alkanoyl 
tyramine analogues are also effective inhibitors of estrone sulfatase activity in human 
breast cancer cells. It was also shown that both C14 and estrone-3-sulfamate are 
irreversible  inhibitors of the estrone sulfatase enzyme [46]. 
A 
 
 
 
B 
 
 
 
 
Figure 6:  A: Chemical structure of (p-O-sulfamoyl)-N-alkanoyl tyramines B: (p-
O-sulfamoyl)-N-tetradecanoyl tyramine (C2-14 also known as DU-14) 
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7. Passive/ Inhibitory Avoidance Behavior and Memory  
 
Passive avoidance learning is a generic term for learning to avoid aversive stimuli 
by "not taking a certain action".  The paradigm requires the subject not to initiate a 
specific type of behavior, usually escape or avoidance, in order to preclude the 
administration of an aversive event [47]. The most common paradigm is passive 
avoidance learning of the step-through type.  Inhibitory avoidance, also frequently 
referred to as passive avoidance, requires that subjects (typically rodents) behave in a 
manner contrary to their normal inclination or predilection.  In most cases, subjects must 
act if they are to avoid the consequences of a negative reinforcer.  During the training 
component of the task, the animal is punished for making an instinctive response, such as 
moving from a brightly lit chamber into a darkened one (a highly probable event for 
rodents).  Passive avoidance learning is believed to be based on contextual memory, 
which is associated with the place and the event of "being given the electric shock in the 
dark box". The hippocampus plays an important role in contextual memory; injuries of 
the hippocampus decrease the performance of passive avoidance learning [47].  Passive 
avoidance learning involves not only contextual memory but also amygdala-dependent 
emotional memory, "fear of the dark box".  The performance of passive avoidance 
learning decreases with defects in either contextual memory or emotional memory.  
 
 Inhibitory avoidance behavior and memory assessment.  
This test uses an apparatus with a lighted box and a connected darkened box.  
Because mice/rats prefer a dark place, they naturally move into the dark box when placed 
in the lighted box.  However, when a mouse/rat is given a footshock through the grid 
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floor of the dark box, the animal hesitates to move into the dark box on a subsequent trial.  
The intensity of the shock is the minimum sufficient to cause flinch and vocalization 
[48].  The reason why the mouse/rat hesitates to move into the dark box, which they 
inherently prefer, is due to learning and memory.  The test of passive avoidance learning 
assesses the ability of a mouse/rat to learn and remember the aversive stimulus on the 
basis of time, that is; delay latency before entering the dark box.  
 
Figure 7: The Passive Avoidance Apparatus. 
 
The measurement of the latency (retention test) is usually performed after 24 
hours or more following the administration of the electric footshock.  A prolonged time 
between an electric shock and the test allows memories of a longer duration to be 
examined.  Presumably the longer the avoidance latency, the more efficacious the 
memory process [47].  Traditionally, passive avoidance tasks have been used to evaluate 
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learning and behavioral manipulations.  This type of learning is based on the assumption 
that a biologically probable response terminated by an unpleasant event will be inhibited 
in the future.  The resulting increase in response latency reflects the strength of the 
memory trace [49].  
Potential drawbacks of the inhibitory avoidance paradigms include an often large 
inter-subject variability, and the differing tolerance to shock reported among subjects 
(which is probably one reason for the large number of subjects often required when 
detecting modest changes in task performance).  Another disadvantage of the passive 
avoidance paradigm, at least with respect to other types of delayed response tasks that use 
changeable discriminable stimuli, is that in inhibitory avoidance, a subject can only be 
used for a single trial, and thus cannot serve as its own control.  However, inhibitory 
avoidance is a classic paradigm that is well studied.  The Medline database (1996-1999) 
listed over 600 articles with passive avoidance or inhibitory avoidance as a main subject 
[47].  Thus, in addition to its relative longevity, the method continues to be used 
extensively.   As an example, it was used to substantiate the findings in the quantification 
of hippocampal and caudaoputamen injury 3 or 7 days after cardiopulmonary 
resuscitation (CPR) [47, 49, 50]. 
 
8. SAP Lesioning  
Saporin is a ribosome-inactivating protein, molecular weight 30kD, found in the 
seeds of the plant Saponaria officinalis [51]. 192 IgG-Saporin (SAP) is a chemical 
conjugate of a mouse monoclonal antibody to rat low affinity neurotrophic receptors 
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(p75
NTR
) and the ribosome-inactivating protein [52].  SAP has a molecular weight of 
210kD. Intraventricular injection of SAP in almost complete elimination of LNGFR 
(p75
NTR
)-positive cells in rat [53, 54].  SAP is directed to a cell-surface p75
NTR
 that is 
selectively expressed at high levels on neurons of the cholinergic basal forebrain (CBF). 
The p75
NTR
, is not expressed on the neighboring, non-cholinergic neurons; thus its 
selectivity. The immunotoxin provides researchers with a powerful tool for neuronal 
lesioning that is more specific and effective than chemical, surgical or electrolytic 
lesioning. Various studies have demonstrated both selectivity and efficacy for SAP [54-
56]. 
 
Elimination of Specific Cell Type 
• SAP recognizes p75
NTR
-expressing cells in rat. 
• SAP specifically eliminates the following:  
o Cholinergic neurons of the basal forebrain  
o Medial septum  
o Diagonal band of Broca  
o Nucleus basalis of Meynert  
o Purkinje neurons of the cerebellum  
 
Effective Tool to Study Behavior 
Permanent and selective removal of cholinergic forebrain neurons makes SAP an 
important animal model for the study of the following:  
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• Behavior (cholinergic forebrain function)  
• Neuronal loss (e.g. Alzheimer's disease)  
• Plasticity of other systems in response to loss of cholinergic neurons 
• Replacement therapy  
• Drug effects and dependence [18, 19, 56-58]. 
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C.  Hypothesis, Prediction and Aims 
 
Hypothesis 
 
Inhibition of GABAA  receptors by the inhibitory effect of DU-14 on the steroid sulfatase 
enzyme to increase endogenous levels of sulfated DHEA would counteract the effect of 
cholinergic lesion to the hippocampus and may enhance retention of passive avoidance 
memory in rats 
 
Prediction 
 
Chronic administration of DU-14 can enhance retention of passive avoidance memory in 
rats after selective lesioning of cholinergic neurons of the medial septum  
 
Aim 1  
This tested the effect of footshock intensity on memory retention in rats.  After selective 
lesion of cholinergic neurons of the medial septum, rats were randomly assigned to three 
footshock groups and tested for memory retention. We predicted that an increase in 
footshock intensity would result in an increase in memory retention in CSF but not SAP 
lesioned rats. This would signify that SAP lesioning would impair footshock memory 
retention in rats. 
 
Aim 2 
We tested the effect of chronic DU-14 administration on retention of footshock memory 
function in rats with selective lesion of cholinergic neurons of the medial septum. Rats 
from footshock levels were administered either DU-14 or Vehicle controls and tested at 
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the retention phase. We hypothesized that DU-14 would enhance memory for footshock 
intensity in both CSF and SAP rats. Results obtained displayed DU-14’s functional 
antagonistic property at the GABA receptor, potentiating memory function in SAP 
animals. 
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II. EXPERIMENTALS  
 
A. Materials and Equipments 
 
1. Facilities 
 
Laboratories 
- Mellon Hall of Science, Duquesne University: Rooms 416A & 454 
- Bayer School of Natural and Environmental Sciences, Duquesne University: Animal Facility 
- Salk Hall, University of Pittsburgh, Rooms 1005, 1006, 1015 and 1016 
 
Office  
- Mellon Hall of Science, Duquesne University: Room 417 
 
2. Animals 
Sprague-Dawley male rats 
Hilltop lab Animal Inc. Scottdale, PA 
 
3. Chemicals and drugs 
[H
 3
] acetyl-CoA  
Sigma Inc., St. Louis, MO 
 
192 IgG Saporin (SAP) 
Chemicon, Temecula, CA 
 
Acetonitrile  
Sigma Inc., St. Louis, MO 
 
Acetyl-CoA 
Sigma Inc., St. Louis, MO 
 
Choline chloride (C5H14ONCl) 
Sigma Inc., St. Louis, MO 
 
Corn Oil 
100% pure Mazola  
Shop and Save, Pittsburgh PA 
 
Disodium phosphate (Na2HPO4)  
Sigma Inc., St. Louis, MO 
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EcoLume
TM  
  Liquid scintillation fluid  
MP Biomedicals, Scottdale, OH  
 
Econofluor scintillation cocktail 
PerkinElmer Life And Analytical Sciences, Inc., IL  
EDTA (Ethylene diamine Tetraacetic acid)  
Fisher Chemicals 
 
Halothane, USP / Isoflurane, USP 
Abbott Laboratories, North Chicago, IL 
 
Ibuprofen Sodium 
Sigma Chemical Co., St Louis, MO 
 
 
Pentobarbital Sodium 
Sigma Chemical Co., St Louis, MO 
  
Physostigmine (eserine salicylate) 
Sigma Inc., St. Louis, MO 
 
Sodium chloride (NaCI)  
Sigma Inc., St. Louis, MO 
 
Sodium phosphate monobasic monohydrate (NaH2PO4.H20) 
Sigma Inc., St. Louis, MO 
 
Sodium tetraphenylborone 
TCI America, Portland, OR 
  
Triton
®
 X-100 
Sigma Inc., St. Louis, MO 
 
4. Materials  
BD disposable syringes (1.0cc) 
Becton Dickson and Company, Franklin Lakes, NJ 
 
DC Protein Assay kit 
Bio-Rad laboratories, Hercules, CA  
 
Disposable Scintillation Vials 
Fisher Scientific, Pittsburgh, PA 
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MLA Precision pipette tips (10, 20-250 and 20-1000µl) 
Fisher Scientific Pittsburgh, PA 
Monosof Black Nylon Suture 
4-0. 3/8: 19mm 
Tyco Health Care, Norwalk, CT 
 
Precision glide® disposable syringes needles (21, 23 and 26 gauge) 
Becton Dickson and Company, Franklin Lakes, NJ 
 
Pipetters, Gilson Pipetman (P0.5, P10, P20, P200, P1000 and P5000) 
Fisher Scientific Pittsburgh, PA 
 
5. Equipments 
 
1209 Rackbeta liquid scintillation counter 
LKB Wallac 
 
Brinkmann Bottle top Dispenser 
Brinkmann instruments, Inc. 
 
DECpc 433sx LP computer (integrated with Gemini System) 
Digital Equipment Corporation, Maynard, MA 
 
Gemini Passive Avoidance System 
San Diego Instruments, Inc., San Diego, CA 
 
Stereotaxic frame  
Stoelting, Wood Dale, IL 
 
VirSonic 475 ultrasonic tissue disruptor  
VirTis 
 
6. Computer Software 
 
Gemini Avoidance Software 
San Diego Instruments, San Diego, CA 
 
Graph pad prism version 3.02 
Graph pad software, San Diego, CA 
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Graph pad prism version 5.01 
Graph pad software, San Diego, CA 
 
Microsoft word& Excel 2003 
Microsoft Corporation, Orem, UT 
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B. Methodology and Procedures 
1. Animal Condition 
All procedures involving the use of animals were in accord with standards 
established by the Animal Welfare Act and approved by the Institutional Animal Care 
and Use Committee of Duquesne University.  Male Sprague-Dawley rats weighing 
approximately 275 grams were purchased from hilltop lab Animal Inc. (Scottdale, PA) 
and individually housed in a well ventilated, temperature and humidity controlled facility 
(22-25 degrees centigrade, 50-75% humidity).  A standard 12 hour light and 12 hour dark 
cycle was maintained. Standard laboratory rat chow and water were available ad libitum.  
The animals were allowed a minimum period of five days to acclimate to the housing 
conditions, before any experiments were performed. 
 
2. Animal Surgery 
Male Sprague-Dawley rats weighing approximately 300 grams were anesthetized 
with pentobarbital (50mg/kg: i.p., of a 50mg/ml stock solution), shaved and then placed 
in a stereotaxic frame (Stoelting, Wood Dale, IL).  An incision was made exposing the 
dorsal aspect of the skull and a small hole, 2mm in diameter was drilled, through which a 
stainless steel cannula was placed into the medial septum, using coordinates from 
Bregma: AP+0.2mm L 0.0, DV-5.4mm.  Animals received either SAP, 0.22µg/µl or CSF 
(sham control) 1µl infused into the medial septum over 5 min at a rate of 0.2µl/min.  
Following infusion, the cannula was left in place for 5 min to allow diffusion into the 
tissues before the withdrawal of the cannula. The incision was closed and rats were 
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administered Ibuprofen (1 ml/kg i.p., of a 10mg/ml stock solution).  Rats remained 
anesthetized throughout the surgery and were allowed to recover for at least one week. 
 
3. Passive Avoidance Testing 
To assess memory retention, a Gemini Avoidance System (San Diego 
instruments) was used with a modified passive avoidance paradigm.  The avoidance 
apparatus consisted of a box (53x53x32cm) with 2 compartments connected by an 
opening with a computer controlled sliding door.  The compartment in which the rats 
were placed was illuminated, while the other compartment remained dark throughout the 
experiment. 
There were three stages of the behavioral testing: the acclimation phase, the 
acquisition phase and the retention phase.  During the acclimation trials that preceded the 
acquisition phase, rats were allowed to explore the apparatus.  The latency period, which 
was the time it took for the rat to cross into the dark compartment, was recorded.  During 
the acquisition trials, rats were placed in the lighted compartment.  After five seconds of 
adaptation, the rats were given a maximum trial duration of 300 sec to cross to the 
darkened chamber.  If the animal entered the dark compartment, the sliding door closed 
and a mild footshock of either 0 mA, 1.0 mA or 1.25 mA for 1 sec was delivered. The 1.0 
mA footshock was selected based on previous studies in our laboratory, 1.25 mA was a 
mild increase while the 0 mA was used as a negative control.  The rat was then removed 
from the chamber and tested again after 5 min. This procedure was repeated until the 
animal spent 300 sec in the lighted chamber two consecutive times within a maximum of 
5 trials.  The number of trials to reach criterion was recorded.  After the acquisition trial, 
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starting from the second day, the animal was administered either DU-14 (30mg/kg, i.p.) 
or corn oil (1ml/kg, i.p.) for 6 consecutive days.  3 hours after drug administration on the 
last day of dosing, the animal was again placed in the lighted compartment and the 
crossover latency recorded.  If a rat did not enter the dark compartment within 600 sec, it 
was removed from the apparatus, and the latency recorded as 600 sec.  Memory retention 
was assessed as an increased crossover latency period during the second trial. 
 
4. ChAT (Choline Acetyltransferase) Assay 
At the completion of behavioral training, all animals were processed for the 
quantification of ChAT activity in the frontal cortex and hippocampus.  Animals were 
anesthetized with 5% halothane or isoflurane in oxygen, decapitated, brains removed, and 
tissues from the frontal cortex (FX), medial septum (MS), and hippocampus (HIPP) 
dissected, frozen at 80ºC and processed at a later time.  Tissues were not pooled.  On the 
day of the assay, frozen tissues were thawed at 4ºC and dissociated by sonication in a 
medium containing EDTA (10mM) and Triton X-100 (0.5%) and diluted to a 
concentration of 10µl/mg tissue.  An aliquot of each sample was used for the 
determination of total protein [58].  Three 5µl aliquots of each sample were incubated for 
30 min in a medium containing 0.25 mM [H
3
]-Acetyl-CoA, 50 mM sodium phosphate 
buffer (pH 7.4); 300 mM sodium chloride, 10 mM choline chloride, 10 mM EDTA and 
0.2 mM physostigmine sulfate were used.  The reaction was stopped by adding 4ml of 10 
mM sodium phosphate buffer (pH 7.4) followed by the addition of 1.6 ml of acetonitrile 
containing 5mg/ml tetraphenylboron in scintillation vials. The amount of [H
3
] – 
acetylcholine produced was determined by adding 8 ml of EconoFluor scintillation 
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cocktail and counting total cpm in the organic phase using an LKB beta-counter.  
Background was determined using identical tubes to which no sample was added.  For 
each sample, the three reaction tubes containing sample were averaged and the difference 
between total cpm and background cpm was used to estimate the total amount of ACh 
produced per sample. The ChAT enzyme activity was expressed as pmol acetylcholine 
production/h/µg protein.  All results obtained from rats associated with values either 
below 62.5% mean normal ChAT activity in the frontal cortex (CSF/FX), or above 62.5% 
mean normal ChAT activity in the hippocampus (CSF/HIPP) were excluded from the 
entire study. 
 
5. Statistical Analysis 
All analyses were performed using the GraphPad Prism 3.02 version while all 
graphs were drawn using GraphPad Prism 5.01 version.  Differences in ChAT activity in 
the HIPP and FX of SAP treated and control animals were compared using the one-way 
ANOVA with a Neuman-Keuls post-hoc test.  Differences in crossover latency were 
determined by statistical analysis utilizing the Student’s t-test, Kruskal-Wallis analysis 
with a Dunnett’s test post-hoc or a two-way ANOVA with surgery and footshock 
intensity as parameters.  Significant differences were interpreted as p<0.05.  The effect of 
frontal cortex lesioning on acclimation crossover latency was examined using the 
correlation analysis.  
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6. Preparation and Administration of Drugs 
DU-14 was prepared by suspending 30mg of crystals in 1 ml of corn oil.  
Ibuprofen solutions were prepared by dissolving 1g in 100mls of deionized water.  The 
route of administration for all drugs was intraperitoneal (IP) using a 23 or 21 gauge 
needle for the administration of DU-14 and a 26 gauge needle for the administration of 
corn oil, pentobarbital and Ibuprofen. 5% halothane or isoflurane in oxygen was 
administered via inhalation. 
 
7. Animal Studies 
a. Effect of  footshock on memory retention 
b. Effect of DU-14 on memory retention 
c. Effect of DU-14 on locomotor activity 
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III. RESULTS AND DISCUSSION 
 
A. Results 
 
1. The effect of 192 IgG-Saporin (SAP) infusion on choline acetyltransferase enzyme 
(ChAT) activity in frontal cortex and hippocampus   
 After behavioral studies, rats were anesthetized and decapitated. One frontal 
cortex and two hippocampal tissues were collected from each rat brain.  The tissues were 
immediately frozen and later analyzed for ChAT activity.  ChAT activity was measured 
to determine presence or absence of cholinergic neurons in the frontal cortex and 
hippocampal tissues after SAP infusion.  A significant decrease in enzyme activity was 
observed in hippocampal tissues from rats infused with SAP compared to control animals 
(p<0.0001; Figure 8). There was no significant change in ChAT activity in frontal cortex 
tissues in SAP treated animals (p>0.05).  All results obtained from rats associated with 
values either below 62.5% mean normal ChAT activity in the frontal cortex (CSF/FX), or 
above 62.5% mean normal ChAT activity in the hippocampus (CSF/HIPP) were excluded 
from the entire study. 
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Figure 8: ChAT activity (Corn oil treated rats) 
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Figure 8:  ChAT activity (Corn oil treated rats) 
 Scatter plots show the effect of SAP lesions on ChAT activity in the frontal cortex 
(SAP/FX) and hippocampus (SAP/HIPP) relative to control (CSF/FX and CSF/SAP). 
Infusion of 192 IgG-Saporin produced a significant decrease in ChAT activity in neurons 
projecting to the hippocampus but not the frontal cortex.  Lines show group mean + 
SEM. Individual data points are also shown.  All data were analyzed by one-way 
ANOVA (F= 63.15; 3, 109 df; p<0.0001) followed by a Newman-Keuls Multiple 
Comparison test where significance was defined as p<0.001, and *** represents a 
significant decrease in the SAP/HIPP group from all other treatment groups. There was 
an 80.3% decrease in ChAT activity in hippocampus of SAP versus CSF rats (7.07 + 0.98 
versus 35.90 + 1.26 pmol ACh produced/hr/µg protein; p<0.001). 
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2. The effect of SAP lesioning on acclimation/ locomotion 
 To assess whether SAP lesioning had an effect on exploratory behavior or 
locomotor activity, seven days following intraseptal infusion of either SAP or CSF 
control, rats acclimated to a standard passive avoidance apparatus.  There was a 
significant increase in the acclimation crossover latency in SAP treated animals (Figure 
9). 
 
Figure 9:  Effect of SAP lesioning on acclimation 
 
 
 
 
 
 
 
 
 
 
Figure 9: Effect of SAP lesioning on acclimation 
 Graph shows the crossover latency in seconds versus the treatment groups. A 
significant increase in crossover latency was seen for SAP treated animals.  Bars 
represent the mean + SEM.  All data were analyzed using the Student’s t-test (p<0.0001). 
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3. Effect of shock intensity on memory acquisition 
 In this set of experiments, animals acquired memory for footshock of different 
intensities. This test was also carried out to determine the optimal shock intensity for the 
study and the effect of shock intensity on the acquisition and retention phases of the 
passive avoidance test.  Following acclimation, rats were randomly assigned to three 
different groups (0 mA (no shock), 1.0 mA, and 1.25 mA). The criterion for selection is 
stated in the methods section.  Figure 10 shows the number of trials to reach criterion for 
control and SAP rats from the 1.0 mA and 1.25 mA shock levels.  Since there was no 
memory to acquire at 0 mA, no representative graphs were shown.  The results show no 
significant difference in acquisition of memory between SAP and control rats for 
footshock at either 1.0 mA or 1.25 mA shock intensities (Figure 10).  However, no 
animal in the SAP/1.25 mA group required more than a single shock to reach criterion. 
 
Figure 10: Effect of shock intensity on memory acquisition 
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Figure 10: Effect of shock intensity on memory acquisition 
 The number of trials to reach criterion was compared for two different shock 
intensities: 1.0 mA and 1.25 mA.  Bars represent the mean + SEM.  A two-way ANOVA 
found neither a SAP nor a shock intensity effect on acquisition of footshock memory 
(Surgery p = 0.066; Shock intensity p<0.87; interaction p= 0.68). 
 
4.  Effect of  footshock on retention 
 CSF and SAP rats from the acquisition phase were dosed for six days with corn 
oil, and then tested on the sixth day of dosing for retention of footshock memory.  Rats 
assigned to the 0 mA footshock group also learned the maze without exposure to 
footshock. They were passed through the apparatus in a similar fashion as the other 
groups allowing for five minute inter-trial intervals for a maximum of 3 trials.  During the 
retention test, all rats in the 0mA footshock intensity group crossed over in less than 100 
sec similar to results observed during the acclimation phase.  There was a non-significant 
increase in retention crossover latency in SAP rats at all shock levels, 0 mA, 1.0 mA and 
1.25 mA with p values of 0.07, 0.1672 and .00992 respectively.  An increase in shock 
intensity produced an increase in retention crossover latency in both CSF and SAP rats. 
In both groups however, there were no significant differences in crossover latency 
between rats administered 1.0mA and 1.25mA footshock (Figure 11).    
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Figure 11:  
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Figure 11:   Effect of footshock intensity on retention 
 Scatter dot plots show the effect of footshock intensity on memory retention. 
Lines show the median with interquartile range.  Individual data points are also shown. 
All data were analyzed by a Kruskal-Wallis non-parametric test (p<0.0005) followed by a 
Dunn’s multiple comparison test where * and ** represent significant differences from 
CSF/0mA; p<0.05 and p<0.05 respectively and 
#
 represents a significant difference from 
SAP/0mA; p< 0.01. 
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5. The effect of  192 IgG-Saporin (SAP) infusion on choline acetyltransferase 
enzyme (ChAT) activity on rats’ frontal cortex and hippocampal tissues  (DU-14 
rats) 
 ChAT activity was measured in DU-14 treated rats to assess the degree of 
cholinergic innervation of the frontal cortex and hippocampus following SAP infusion. 
One frontal cortex and two hippocampal tissues were collected from each rat brain.  SAP 
infusion into the medial septum produced a significant decrease in enzyme activity in the 
brain hippocampal tissues (p<0.0001; Figure 12).  There was also a significant effect of 
SAP lesion on frontal cortex ChAT activity when compared to CSF frontal cortex group 
(p< 0.05).  All results obtained from rats associated with values either below 62.5% mean 
normal ChAT activity in the frontal cortex (CSF/FX), or above 62.5% mean normal 
ChAT activity in the hippocampus (CSF/HIPP) were excluded from the entire study. 
 
 Figure 12: Effect of 192 SAP infusions on ChAT activity in frontal cortex and 
hippocampal tissues (DU-14 rats)  
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Figure 12:  Effect of 192 IgG-Saporin (SAP) infusions on choline acetyltransferase 
enzyme (ChAT) on rats’ frontal cortex and hippocampal tissues (DU-14 rats) 
 Scatter dot plots show the effect of SAP lesions on ChAT activity in the frontal 
cortex (SAP/FX) and hippocampus (SAP/HIPP) relative to control (CSF/FX and 
CSF/SAP).  Infusion of 192 IgG-Saporin produced a significant decrease in ChAT 
activity in neurons projecting to the hippocampus but not the frontal cortex. Lines show 
group mean + SEM.  Individual data points are also shown.  All data were analyzed by 
one-way ANOVA (F=52.02; 3, 106 df; p<0.0001) followed by a Newman-Keuls 
Multiple Comparison test where significance was defined as p<0.001, and *** represents 
a significant decrease in the SAP/HIPP group from all other treatment groups.  There was 
an 80.9% decrease in ChAT activity in hippocampi of SAP versus CSF rats (6.95 + 1.02 
versus 36.31 + 1.20 pmol ACh produced/hr/µg protein; p< 0.001).  There was also a 
24.1% decrease in ChAT activity in the frontal cortex of SAP rats when compared to 
similar tissues in CSF rats (30.07 + 5.70 versus 40.41 + 2.22 pmol ACh produced/hr/µg 
protein;** p< 0.001).  
 
6. Effect of frontal cortex lesion on acclimation/ locomotion in rats 
 A significant decrease was seen in the frontal cortex of SAP treated animals when 
compared to those of CSF infused rats. Thus, there was a possibility for the loss of 
cholinergic tone in the frontal cortex that could affect rat’s locomotor activity.  A 
spearman’s correlation analysis was performed to predict the relationship between 
cholinergic denervations of specific regions of the brain and behavioral performance.  All 
SAP rats were first examined and then further grouped based on lesioned region.  Groups 
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were SAP infused rats with lesions in the hippocampus but not the frontal cortex (No FX 
lesion) and SAP infused rats with lesions in both the hippocampus and frontal cortex 
(FX+HC lesion).  SAP lesioning in the frontal cortex or hippocampus was defined as 
62.5% below mean normal ChAT activity of CSF/FX or CSF/SAP groups respectively 
(Figure 12). Extent of lesioning showed no correlation to acclimation crossover latency 
(sr=0.1036, 0.2000 and -0.4524; Figure 13). 
 
Figure 13: Effect of Frontal cortex lesion on acclimation/locomotion  
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Figure 13: Effect of frontal cortex lesion on acclimation/ locomotion in rats 
 Scatter plots show relationship between the ChAT activity and acclimation 
crossover latency. All data were analyzed by the Spearman’s Rho non-parametric 
correlation analysis. A: In all SAP treated rats, there was an insignificant correlation 
seen; (sr=0.1036, p=0.7134). With rats further divided based lesioned region of the 
brains, B: In rats No FX lesion rats an insignificant correlation was observed (sr=0.2000, 
p=0.7139). Likewise in rats with lesions in both the frontal cortex and the hippocampus, 
C:  an insignificant correlation was observed (sr=-0.4524, p=0.2675). 
 
7. Effect of DU-14 on memory retention after 1.0mA footshock administration 
 
 To determine the effect of DU-14 on retention memory, rats were tested using 
passive avoidance as described previously.  Rats were tested for memory retention after 6 
days of DU-14 dosing. As seen in Figure 14, treatment with DU-14 significantly 
increased crossover latency in SAP treated animals (p=0.0476).  There was also a non-
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significant increase in the crossover latency in control animals treated with DU-14 
(p=0.1563).  
 
Figure 14:  
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Figure 14: Effect of DU-14 on memory retention after administration of 1.0mA 
footshock 
 
 Scatter dot plot shows the effect of DU-14 administration on memory.  Lines 
show the median with interquartile range.  Individual data points were also shown. All 
data were analyzed by a Kruskal-Wallis non-parametric test (p=0.0476) followed by a 
Dunn’s multiple comparison test where * represents a significant difference from 
SAP/Co; p<0.05. 
 
  
  
49 
 
8. Effect of DU-14 on memory retention after 1.25mA footshock administration 
 
 The effect of DU-14 on memory retention was also tested in rats after 1.25mA 
footshock administration. Rats were tested for memory retention after six days of DU-14 
dosing. DU-14 produced no significant change in the crossover latency in either control 
or SAP animals. 
 
 
Figure 15:  Effect of DU-14 on memory retention after administration of 1.25mA 
footshock 
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Figure 15: Effect of DU-14 on memory retention after administration of 1.25mA 
footshock 
 
 Scatter dot plot shows the effect of DU-14 administration on memory.  Lines 
show the median with interquartile range. Individual data points were also shown. All 
data were analyzed by a Kruskal-Wallis non-parametric test (p=0.4029). No significances 
were seen among groups. 
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9. Effect of DU-14 on locomotion 
 
 One possible explanation for the DU-14 effect seen in Figure 14 was a possible 
effect of the drug on locomotor activity.  Perhaps after 6 days of dosing, rather than 
enhance memory retention, DU-14 treatment affected locomotor activity. It was therefore 
necessary to perform the acclimation test with a separate group of rats after dosing with 
DU-14.  Rats (CSF and SAP) dosed with DU-14 for 6 days one week after surgery 
showed no significant differences from untreated rats (CSF and SAP) in crossover 
latency when tested during the acclimation phase, before acquisition of footshock. No 
DU-14 effect was seen on spontaneous locomotor activity (Figure 16a).  Another set of 
experiment was carried out to determine the effect of DU-14 on locomotion after the 
retention phase. Rats administered no footshock during the acquisition phase were tested 
for 0 mA footshock memory retention after six day of dosing with either DU-14 or corn 
oil (vehicle). There was no significant difference between rats treated with DU-14 and 
corn oil (Figure 16b). 
 
Figure 16a: Effect of DU-14 on locomotion (acclimation phase) 
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Figure 16a: Effect of DU-14 on locomotion (acclimation phase) 
 
 Each bar represent the mean + SEM.  There was no significant DU-14 effect on 
spontaneous locomotor activity. All data were analyzed Kruskal-Wallis test (p = 0.0003) 
followed by a Dunn’s multiple comparison test where *** represents a significant 
difference from CSF; p< 0.0001.  The significant difference seen between CSF and SAP 
groups has previously been established in Figure 9. 
 
 
Figure 16b: Effect of DU-14 on locomotion (retention phase) 
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Figure 16b: Effect of DU-14 on locomotion (retention phase) 
 
 Each bar represent the mean + SEM.  There was no significant difference in 
crossover latency between rats treated with DU-14 and corn oil.  All data were analyzed 
Kruskal-Wallis test (p=0.1468).   
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 B. Discussion 
In this study, we showed that infusion of SAP decreased cholinergic innervation 
of the hippocampus, a model that has been used in the past to mimic memory impairment 
as seen in Alzheimer’s disease [54, 56]. We also showed that SAP lesioning affected 
spontaneous locomotor/exploratory behavior, an effect that has not been previously 
reported.  Nevertheless, the change in locomotor activity did not totally impair 
exploratory behavior because rats crossed over to the darkened chamber in less than 100 
seconds during the acclimation phase of the experiments. 
In the past, various footshock intensities ranging from 0.2 to 1.0 mA had been 
used in passive avoidance experiments [5, 47-49, 59, 60].  Therefore, it was necessary to 
determine the effect of footshock intensity on memory acquisition and retention, and how 
increased shock intensity would affect retention crossover latency.  There was a non-
significant decrease in the number of footshocks required by SAP rats to acquire the task 
in both the 1.0mA and 1.25mA groups compared to CSF rats.  It was, however, 
interesting that, without exception, all SAP, but not all control 1.25mA rats required no 
more than a single footshock to reach criterion.  The effect observed with the SAP rats 
requiring fewer footshocks to reach criterion, though statistically insignificant, 
nonetheless suggests the possibility of either heightened sensitivity to the footshock or 
enhanced aversion if the perceived intensity was the same as for control animals.  In 
addition, since SAP treatment significantly increased crossover latency, both responses to 
SAP treatment might have a synergistic effect to increase crossover latency at the higher 
shock intensity.  
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To determine the effect of footshock on memory retention, following the 
acquisition phase, rats were tested for retention of footshock memory on the sixth (6th) 
day of dosing with corn oil.  Rats administered 0 mA footshock exhibited no significant 
difference in the retention (figure 11) and the crossover latency remained similar to 
latencies observed during acclimation phase. This suggests that any increase in retention 
crossover latency after shock (1.0/ 1.25 mA) administration was as a result of memory for 
actual shock. 
Rats in the 1.0 mA footshock group had over a five fold increase in retention 
crossover latency when compared to the acclimation phase in both CSF and SAP lesioned 
rats.  There was also an increase in retention crossover latency in the SAP/1.0mA group 
when compared to the CSF/1.0mA. This increase was however, not significant.  
Surprisingly, the results of these experiments were inconsistent with previous findings.  
Samreen Arshad in her study reported that intraseptal infusion of SAP into the medial 
septum produced a significant reduction in retention crossover latency in rats [61].  
Several factors, however, may have contributed to the differing results.  First, the rats in 
Ms. Arshad’s study did not receive daily injections.  Intra-peritioneal injection is an 
aversive stimulus and thus may have attenuated the expected impairment in retention in 
the passive avoidance experiment [58].  Stress is known to cause elevations in 
neuroactive steroid levels, in particular a derivative of corticosterone, the neurosteroid 
tetrahydrodeoxycorticosterone (THDOC), as well as alloprenanolone [62].   Belz et al. 
[63] demonstrated that daily stimulation with an IP injection of saline would act as a mild 
stressor and induce elevations of plasma corticosterone.  Moreover, Fitz et al. [58] 
reported that IP injection prior to training eliminated the impairment  induced by 
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hippocampal cholinergic lesion on acquisition of a DMP task.  These authors concluded 
that the introduction of a mild stressor reduced impairment produced by the hippocampal 
cholinergic lesion.  These results were consistent with the relative lack of effect of 
hippocampal SAP lesion on acquisition of the more stressful MWM task [64].  The study 
demonstrated that an aversive stimulus consisting of daily injection would mask expected 
memory impairment caused by SAP infusion [58].  Similarly, for rats administered a 
higher footshock intensity of 1.25 mA, there was over a 10 fold increase in retention 
crossover latency (Figure 11) when compared to acclimation crossover latency (Figure 
9).  The increase seen in SAP/1.25mA rats when compared to the CSF/1.25mA rats was 
not significant, which again may have been due to the daily injection of rats over six 
days.   
Considering the capacity of the brain to adjust for alterations in neuronal activity, 
it is possible that with a chronic loss of cholinergic tone in the hippocampus following 
SAP infusion, neuronal remodeling may compensate to support GABAergic and/or 
glutamertergic neurotransmission to levels that preserve memory function at normal or 
near normal levels [65]. Thus an alternative explanation for the SAP effect and/or trend 
observed in these experiments may be due to the possibility that damage to one memory 
system might enhance learning mediated by another [66] as demonstrated by Matthew 
and Best where they showed that fimbria/fornix lesion facilitated  learning in a non-
spatial task compared to non-lesioned rats.  Such that the intact animal is biased to 
process space because of functioning spatial cognitive map whereas the lesioned animal 
suffers no such bias, relying on the intact region in the brain.  This explanation supports 
the view that multiple memory systems compete and are integrated to form a cognitive 
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response [67], and as an example, regions of the brain such as the amygdala play a role in 
fear memory retention in the passive avoidance paradigm.   
It may be worthwhile in the future, in order to eliminate the aversive aspect of IP 
drug administration, to design a study that would use a less stressful route to administer 
the drugs such as a single depot injection.  
The increase in footshock intensity from 0 mA to 1.0 mA produced a significant 
increase in retention crossover latency.  There was a further increase in latency with 
administration of 1.25 mA footshock. However, the increase in retention crossover 
latency from 1.0 mA to 1.25 mA was not significant.  A similar trend was seen with SAP 
treated rats with increased footshock intensity resulting in a corresponding increase in 
crossover latency.  Since there was no significant impairment of ChAT activity in the 
frontal cortex in corn oil treated rats, our data support the role of the hippocampus in 
spatial learning and working memory as opposed to fear learning in our study [68, 69].  
The next set of experiments was carried out in order to determine the effect of 
DU-14 on footshock memory retention.  An assay for the ChAT enzyme was performed 
on the hippocampi and frontal cortex from rats in this group to determine whether 
cholinergic lesion was successful in those specific regions of the brain.  Results 
demonstrated appropriate lesion in the hippocampus, however, there was a significant 
24.1% reduction in ChAT activity in the frontal cortex as well.  This finding suggests the 
possibility that retention latency may have been affected as a result of impairment of 
frontal cortical function in addition to the hippocampus.  After examining the correlation 
between the frontal cortex lesion and acclimation crossover latency (Figure 13), the 
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decrease in mean ChAT activity in the frontal cortex tissues of SAP treated rats did not 
seem to affect rats’ exploratory behavior (Figure 13). 
After 1.0mA footshock, SAP treated rats administered DU-14 had a significant 
increase in crossover latency when compared to control rats.  Previous articles have 
demonstrated that animals chronically treated with DU-14 had increased plasma DHEAS 
and enhanced hippocampal acetylcholine release.  There was also a reduction of 
scopolamine induced amnesia utilizing a passive avoidance paradigm [70, 71].  The 
steroid sulfatase inhibitor effect had previously been demonstrated in rats with 
scopolamine induced amnesia but not untreated animals [70, 72].  By inhibiting the 
metabolism of DHEAS to DHEA, DU-14 could increase endogenous levels of DHEAS 
which would then decrease GABAergic inhibitory tone on cholinergic neurons of the 
basal forebrain [5]. This could explain the increase in hippocampal ACh and the observed 
decrease in scopolamine induced amnesia observed in previous studies [70].  Similarly, 
Arshad in her study showed that DHEAS at 10mg/kg would diminish memory deficits in 
rats after selective lesion to the hippocampus but had no effect in control rats [61].  This 
result further suggests and supports the finding that DU-14 has the potential to enhance 
memory function in patients with cholinergic deficits e.g. in Alzheimer’s disease. A 
possible advantage of DU-14 administration over DHEAS is that it not only elevates the 
endogenous DHEAS levels but other steroids such as estrone sulfate, pregnenolone 
sulfate and cholesterol sulfate which have also been implicated in memory enhancement.  
DU-14 may be an effective therapeutic tool when co-administered with other memory 
enhancing medications which differ in their mechanism of action. This would lower 
individual medication dose as well as minimize observable side effects. 
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At the 1.25 mA footshock level, DU-14 had no significant effect on retention 
crossover latency in either control or SAP animals.  This result suggests that the level of 
shock intensity in addition to daily injections may induce a degree of arousal above a 
level to produce a differential effect in control and SAP treated animals.  Interestingly, a 
similar suggestion was proposed by Carmen Sandi stating that interference with long-
term memory formation by the blockade of brain glucocorticoid receptors (GRs) might be 
effective only for learning situations that involve a moderate stress component, but 
ineffective when dealing with more traumatic experiences [60]. Consistent with this 
finding, there are a number of studies in the literature that report  different intensities of 
stressful stimuli can induce either impairment or facilitation of memory [60, 73, 74]. 
Activation of the physiological stress response results in an elevation of glucocorticoid 
levels.  Given the lipophilic nature of glucocorticoids, they can easily cross the blood-
brain barrier and enter the brain where they can influence brain function and behavior via 
binding to different receptor types [60].  Thus, consistent with the results of the Fitz 
study, the 1.25mA shock in addition to the daily IP injections could act synergistically to 
attenuate the SAP effect expected.  
Finally, this study demonstrated that DU-14 delayed crossover latency via 
enhancement of retention, since DU-14 administration was found to neither affect 
acclimation nor retention crossover latency (Figures 16a & 16b) when footshock was not 
administered during the experiment. 
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IV. CONCLUSIONS 
 
 
The results of these experiments support previous findings that chronic DU-14 
administration enhances memory function in rats with cholinergic impairment of the 
CNS.  The memory enhancing properties of DU-14 may potentially enhance memory 
function in patients with dementia e.g. Alzheimer’s disease.  DU-14 has the potential to 
become a therapeutic tool when co-administered with other memory enhancing 
medication with a different mechanism of action. This would not only lower individual 
medication dose but minimize observable side effect. 
A finding from this study was that SAP had a small but significant effect on 
locomotor activity.  While SAP did not decrease the rats’ exploratory behavior, it was 
shown that SAP treatment decreased spontaneous locomotor activity. Thus, in addition to 
memory function, the hippocampus may have an effect on motivation and/or spontaneous 
exploration in rats. The effect of SAP could possibly also be attributed to sensitization of 
sensory receptors in the footpads. 
Finally, aversive stimuli either in the form of daily injection in rats, or by 
administration of specific footshock intensity (in this case, 1.25mA footshock intensity) 
was found to attenuate memory differences between SAP and control animals. While 
these results support previous findings in our laboratory, it would be worthwhile in future 
research to study SAP treated rats using a passive avoidance paradigm without the 
aversion produced by daily injections either by administering a single depot injection of 
DU-14, or a less aversive method of administration such as oral administration. 
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